Alpine Immune Sciences Inc (NASDAQ:ALPN)
| 8.27 Delayed Data As of 4:00pm ET |  +0.02 / +0.24%Today’s Change | 6.00 Today|||52-Week Range 14.40 | -40.29% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $250.2M |
Company Description
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovery of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases, immuno-oncology, and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA.
Contact Information
Alpine Immune Sciences, Inc. 188 East Blaine Street Seattle Washington 98102 |
Employees
Shareholders
| Mutual fund holders | 6.22% |
| Individual stakeholders | 45.75% |
| Other institutional | 26.19% |
Top Executives
| Mitchell H. Gold | Executive Chairman & Chief Executive Officer |
| Stanford L. Peng | President & Head-Research & Development |
| Thaedra Thullberry | Finance Director |
| James Paul Rickey | Chief Financial Officer, Secretary & Senior VP |
| Wayne R. Gombotz | Chief Technology Officer |
